Gotham Asset Management LLC Sells 25,965 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Gotham Asset Management LLC cut its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 28.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,948 shares of the company's stock after selling 25,965 shares during the period. Gotham Asset Management LLC owned 0.14% of Pacira BioSciences worth $1,224,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Balyasny Asset Management L.P. acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at about $8,180,000. Ameriprise Financial Inc. lifted its stake in Pacira BioSciences by 150.1% in the fourth quarter. Ameriprise Financial Inc. now owns 324,261 shares of the company's stock valued at $6,109,000 after buying an additional 194,597 shares during the period. ExodusPoint Capital Management LP boosted its holdings in shares of Pacira BioSciences by 232.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 212,824 shares of the company's stock worth $4,010,000 after buying an additional 148,842 shares in the last quarter. Northern Trust Corp grew its position in shares of Pacira BioSciences by 30.8% during the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock worth $11,622,000 after buying an additional 145,205 shares during the period. Finally, Norges Bank bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at $2,405,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright upped their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Needham & Company LLC reduced their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Barclays boosted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $26.44.

Pacira BioSciences Stock Down 2.3%

PCRX stock traded down $0.61 during mid-day trading on Wednesday, reaching $26.14. 776,958 shares of the company traded hands, compared to its average volume of 971,473. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The firm's 50 day moving average price is $25.04 and its 200 day moving average price is $22.54. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -12.88 and a beta of 0.56. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.64.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.